The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Endothelin-1 Potentiates Human Smooth Muscle Cell Growth to PDGF: Effects of ET A and ET B Receptor Blockade
Abstract
Background —Endothelin-1 (ET-1) is a potent vasoconstrictor. However, its mitogenic effects on vascular smooth muscle cells (SMCs) remain controversial. We investigated the role of ET-1 in human SMC growth and its synergistic effect with platelet-derived growth factor (PDGF). Methods and Results —Human aortic SMCs were cultured and cell proliferation was assayed by [ 3 H]thymidine incorporation. PDGF receptor expression, activation of mitogen-activated protein kinase (MAPK), cell cycle regulators such as cyclin-dependent kinase 2 (Cdk2), Cdk inhibitor (p27 Kip1 ), and retinoblastoma protein (pRb) were analyzed by immunoblotting. ET-1 on its own was unable to stimulate [ 3 H]thymidine incorporation but dramatically potentiated the effect of PDGF-BB up to 6-fold ( P <0.001). Most of the potentiating effects (88%) were blocked by the ET A receptor antagonist LU135252 and slightly further blocked by the ET A/B receptor antagonist bosentan ( P <0.05). ET-1 stimulated MAPK, but it neither potentiated PDGF-induced MAPK activation nor overexpressed PDGF receptors. In contrast to PDGF-BB, ET-1 had no regulatory effects on Cdk2, p27 Kip1 , and pRb. Conclusions —In human SMCs, ET-1 activates MAPK but has no mitogenic effects on its own. However, ET-1 markedly potentiates proliferation to PDGF, mainly via ET A receptors. This may represent an important function of ET-1 for vascular structural changes in patients and provide new therapeutic opportunities for ET-1 receptor antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Cited by
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
Wang, C.-Y., Liu, P.-Y., & Liao, J. K. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.11.004 · Cited by 593
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Anand, I., McMurray, J., Cohn, J. N., Konstam, M. A., Notter, T., Quitzau, K., Ruschitzka, F., & Lüscher, T. F. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16723-8 · Cited by 347
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
Iglarz, M., Binkert, C., Morrison, K., Fischli, W., Gatfield, J., Treiber, A., Weller, T., Bolli, M. H., Boss, C., Buchmann, S., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.142976 · Cited by 329
Metadata
- Authors
- Yang, Z., Krasnici, N., & Lüscher, T. F.
- Venue
- Circulation
- Published
- 1999-07-06
- Volume
- 100
- Issue
- 1
- Pages
- 5-8
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2141243151
- Cited by
- 158
- References
- 1
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endothelin-1 Potentiates Human Smooth Muscle Cell Growth to PDGF: Effects of ET A and ET B Receptor Blockade. https://app.cochat.ai/papers/10.1161/01.cir.100.1.5
- The paper
- Yang, Z., Krasnici, N., & Lüscher, T. F. (1999). Endothelin-1 Potentiates Human Smooth Muscle Cell Growth to PDGF: Effects of ET A and ET B Receptor Blockade. Circulation. https://doi.org/10.1161/01.cir.100.1.5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.